Ipca Laboratories Ltd (IPCALAB)
₹1,978.80
Mkt cap
₹49,703 Cr
P/E ratio
36.20
P/B
6.22
Div yield
0.31%
ROE
15.70%
ROCE
17.00%
EPS (TTM)
₹54.66
Book value
₹318
52W range
1,269–1,988
Sector
Healthcare
Price history
Previous close
Ipca Laboratories is an integrated pharmaceutical company manufacturing branded and generic formulations, APIs and intermediates. Indian branded formulations are its core profit engine, complemented by formulation exports across Europe, Africa, the Americas, Asia, CIS and Australasia. The consolidated business includes Unichem Laboratories and its US, Brazil, Europe and South Africa operations. [1]
NSE IPCALABBSE 524494
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−0.44% from high₹1,979
₹1,269+55.97% from low₹1,988
Current
₹1,978.80
Prev close
₹1,962.00
Day
+0.86%
Price performance
1D
+0.86%
1W
−0.44%
1M
+17.38%
3M
+21.38%
6M
+31.84%
1Y
+44.69%
YTD
+40.94%
Financials
Revenue, profit & margin
P/E ratio
36.2×
IPCALAB is 3% above the sector median of 35.1×
IPCALAB36.2×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,585 | 2,034 | 2,053 | 2,033 | 2,093 | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 | 2,392 | 2,388 | 2,788 | |
| Expenses | 1,278 | 1,673 | 1,722 | 1,711 | 1,700 | 1,913 | 1,782 | 1,818 | 1,892 | 2,012 | 1,859 | 1,905 | 2,119 | |
| Operating Profit | 308 | 361 | 331 | 322 | 393 | 441 | 463 | 429 | 416 | 545 | 533 | 484 | 670 | |
| OPM % | 19% | 18% | 16% | 16% | 19% | 19% | 21% | 19% | 18% | 21% | 22% | 20% | 24% | |
| Other Income | 45 | -1 | 91 | -118 | 21 | 26 | 20 | -179 | 33 | -30 | 38 | 48 | 25 | |
| Interest | 31 | 44 | 33 | 29 | 24 | 23 | 17 | 22 | 19 | 20 | 18 | 20 | 12 | |
| Depreciation | 69 | 90 | 100 | 98 | 99 | 100 | 98 | 100 | 100 | 103 | 108 | 107 | 111 | |
| Profit before tax | 252 | 225 | 289 | 77 | 290 | 345 | 368 | 128 | 331 | 392 | 446 | 404 | 572 | |
| Tax % | 34% | 39% | 23% | 96% | 31% | 29% | 25% | 49% | 29% | 28% | 18% | 24% | 26% | |
| Net Profit | 164 | 136 | 221 | 1 | 199 | 246 | 276 | 64 | 233 | 281 | 364 | 307 | 424 | |
| EPS in Rs | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 | 12.86 | 11.79 | 15.84 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.07% · closed higher next day 35 of last 59
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 10 Nov '23◦ | 14 Feb '24◦ | 29 May '24◦ | 13 Aug '24◦ | 14 Nov '24◦ | 13 Feb '25◦ | 29 May '25◦ | 11 Aug '25 | 13 Nov '25 | 13 Feb '26 | 29 May '26 | 13 Aug '26 |
| Earnings day | +0.35% | −0.20% | −3.45% | −3.42% | +1.96% | −1.81% | −3.07% | −3.61% | −2.90% | +0.85% | −3.05% | −3.46% |
| +1 day | +0.63% | +7.51% | −10.96% | −4.22% | +2.47% | −0.95% | −3.69% | −0.73% | +10.34% | +1.51% | −5.21% | +4.92% |
| +5 days | +2.30% | +6.58% | −10.22% | +0.44% | +1.93% | −3.08% | −6.74% | −0.24% | +7.26% | −1.57% | +4.42% | +6.40% |
| +15 days | +7.21% | +2.84% | −12.18% | +3.39% | −0.14% | −10.99% | −7.86% | −2.51% | +8.48% | +2.02% | +0.85% | +9.41% |
| +30 days | +4.66% | +6.83% | −5.44% | +5.88% | +10.18% | −5.03% | −1.39% | −2.77% | +7.38% | +2.40% | +15.96% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202644.72%Promoter
Promoters44.72%
FIIs10.72%0.09
DIIs37.04%0.09
Public7.19%0.02
Government0.32%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| IPCALAB | ₹1,959.10 | 36.19 | 49,703 | 0.31% | 424 | +72.33% | 2,788 | +20.76% | 16.98% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports13
Concall transcripts39
TranscriptAug 2026RECAug 2026TranscriptJun 2026TranscriptFeb 2026RECFeb 2026TranscriptNov 2025RECNov 2025TranscriptAug 2025TranscriptJun 2025PPTJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024TranscriptJun 2024TranscriptFeb 2024TranscriptNov 2023TranscriptAug 2023TranscriptApr 2023TranscriptFeb 2023TranscriptNov 2022TranscriptAug 2022TranscriptMay 2022
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 17 Aug - Ipca Q1 FY27 call: 13% domestic growth, 21% consolidated growth, guidance raised to 14-16% and 23% margin.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 14 Aug - Ipca Laboratories shared audio link for its 14 August 2026 Q1FY27 earnings and business update call.Announcement under Regulation 30 (LODR)-Newspaper Publication 14 AugShareholder Meeting / Postal Ballot-Scrutinizer''s Report 14 Aug - Ipca Laboratories’ 76th AGM on 13 Aug 2026 passed all resolutions, including dividend and director reappointments.Shareholder Meeting / Postal Ballot-Outcome of AGM 13 Aug - Ipca Laboratories held its 76th AGM on 13 August 2026; shareholders considered FY26 results, dividend and director appointments.